Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice

P. Basova, V. Pospisil, F. Savvulidi, P. Burda, K. Vargova, L. Stanek, M. Dluhosova, E. Kuzmova, A. Jonasova, Ulrich G. Steidl, P. Laslo, T. Stopka

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

PU.1 downregulation within hematopoietic stem and progenitor cells (HSPCs) is the primary mechanism for the development of acute myeloid leukemia (AML) in mice with homozygous deletion of the upstream regulatory element (URE) of PU.1 gene. p53 is a well-known tumor suppressor that is often mutated in human hematologic malignancies including AML and adds to their aggressiveness; however, its genetic deletion does not cause AML in mouse. Deletion of p53 in the PU.1ure/ure mice (PU.1ure/ure p53-/) results in more aggressive AML with shortened overall survival. PU.1ure/urep53-/- progenitors express significantly lower PU.1 levels. In addition to URE deletion we searched for other mechanisms that in the absence of p53 contribute to decreased PU.1 levels in PU.1ure/urep53-/- mice. We found involvement of Myb and miR-155 in downregulation of PU.1 in aggressive murine AML. Upon inhibition of either Myb or miR-155 in vitro the AML progenitors restore PU.1 levels and lose leukemic cell growth similarly to PU.1 rescue. The MYB/miR-155/PU.1 axis is a target of p53 and is activated early after p53 loss as indicated by transient p53 knockdown. Furthermore, deregulation of both MYB and miR-155 coupled with PU.1 downregulation was observed in human AML, suggesting that MYB/miR-155/PU.1 mechanism may be involved in the pathogenesis of AML and its aggressiveness characterized by p53 mutation.

Original languageEnglish (US)
Pages (from-to)4735-4745
Number of pages11
JournalOncogene
Volume33
Issue number39
DOIs
StatePublished - Sep 1 2014

Fingerprint

Acute Myeloid Leukemia
Down-Regulation
Hematopoietic Stem Cells
Hematologic Neoplasms
Mutation
Survival
Growth
Genes
Neoplasms

Keywords

  • AML
  • Differentiation
  • Leukemia
  • microRNA
  • p53
  • PU.1

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics
  • Medicine(all)

Cite this

Basova, P., Pospisil, V., Savvulidi, F., Burda, P., Vargova, K., Stanek, L., ... Stopka, T. (2014). Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice. Oncogene, 33(39), 4735-4745. https://doi.org/10.1038/onc.2013.414

Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice. / Basova, P.; Pospisil, V.; Savvulidi, F.; Burda, P.; Vargova, K.; Stanek, L.; Dluhosova, M.; Kuzmova, E.; Jonasova, A.; Steidl, Ulrich G.; Laslo, P.; Stopka, T.

In: Oncogene, Vol. 33, No. 39, 01.09.2014, p. 4735-4745.

Research output: Contribution to journalArticle

Basova, P, Pospisil, V, Savvulidi, F, Burda, P, Vargova, K, Stanek, L, Dluhosova, M, Kuzmova, E, Jonasova, A, Steidl, UG, Laslo, P & Stopka, T 2014, 'Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice', Oncogene, vol. 33, no. 39, pp. 4735-4745. https://doi.org/10.1038/onc.2013.414
Basova P, Pospisil V, Savvulidi F, Burda P, Vargova K, Stanek L et al. Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice. Oncogene. 2014 Sep 1;33(39):4735-4745. https://doi.org/10.1038/onc.2013.414
Basova, P. ; Pospisil, V. ; Savvulidi, F. ; Burda, P. ; Vargova, K. ; Stanek, L. ; Dluhosova, M. ; Kuzmova, E. ; Jonasova, A. ; Steidl, Ulrich G. ; Laslo, P. ; Stopka, T. / Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice. In: Oncogene. 2014 ; Vol. 33, No. 39. pp. 4735-4745.
@article{1f2c9f1fb37e4b4bbee1c8f02b37ad93,
title = "Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice",
abstract = "PU.1 downregulation within hematopoietic stem and progenitor cells (HSPCs) is the primary mechanism for the development of acute myeloid leukemia (AML) in mice with homozygous deletion of the upstream regulatory element (URE) of PU.1 gene. p53 is a well-known tumor suppressor that is often mutated in human hematologic malignancies including AML and adds to their aggressiveness; however, its genetic deletion does not cause AML in mouse. Deletion of p53 in the PU.1ure/ure mice (PU.1ure/ure p53-/) results in more aggressive AML with shortened overall survival. PU.1ure/urep53-/- progenitors express significantly lower PU.1 levels. In addition to URE deletion we searched for other mechanisms that in the absence of p53 contribute to decreased PU.1 levels in PU.1ure/urep53-/- mice. We found involvement of Myb and miR-155 in downregulation of PU.1 in aggressive murine AML. Upon inhibition of either Myb or miR-155 in vitro the AML progenitors restore PU.1 levels and lose leukemic cell growth similarly to PU.1 rescue. The MYB/miR-155/PU.1 axis is a target of p53 and is activated early after p53 loss as indicated by transient p53 knockdown. Furthermore, deregulation of both MYB and miR-155 coupled with PU.1 downregulation was observed in human AML, suggesting that MYB/miR-155/PU.1 mechanism may be involved in the pathogenesis of AML and its aggressiveness characterized by p53 mutation.",
keywords = "AML, Differentiation, Leukemia, microRNA, p53, PU.1",
author = "P. Basova and V. Pospisil and F. Savvulidi and P. Burda and K. Vargova and L. Stanek and M. Dluhosova and E. Kuzmova and A. Jonasova and Steidl, {Ulrich G.} and P. Laslo and T. Stopka",
year = "2014",
month = "9",
day = "1",
doi = "10.1038/onc.2013.414",
language = "English (US)",
volume = "33",
pages = "4735--4745",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "39",

}

TY - JOUR

T1 - Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice

AU - Basova, P.

AU - Pospisil, V.

AU - Savvulidi, F.

AU - Burda, P.

AU - Vargova, K.

AU - Stanek, L.

AU - Dluhosova, M.

AU - Kuzmova, E.

AU - Jonasova, A.

AU - Steidl, Ulrich G.

AU - Laslo, P.

AU - Stopka, T.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - PU.1 downregulation within hematopoietic stem and progenitor cells (HSPCs) is the primary mechanism for the development of acute myeloid leukemia (AML) in mice with homozygous deletion of the upstream regulatory element (URE) of PU.1 gene. p53 is a well-known tumor suppressor that is often mutated in human hematologic malignancies including AML and adds to their aggressiveness; however, its genetic deletion does not cause AML in mouse. Deletion of p53 in the PU.1ure/ure mice (PU.1ure/ure p53-/) results in more aggressive AML with shortened overall survival. PU.1ure/urep53-/- progenitors express significantly lower PU.1 levels. In addition to URE deletion we searched for other mechanisms that in the absence of p53 contribute to decreased PU.1 levels in PU.1ure/urep53-/- mice. We found involvement of Myb and miR-155 in downregulation of PU.1 in aggressive murine AML. Upon inhibition of either Myb or miR-155 in vitro the AML progenitors restore PU.1 levels and lose leukemic cell growth similarly to PU.1 rescue. The MYB/miR-155/PU.1 axis is a target of p53 and is activated early after p53 loss as indicated by transient p53 knockdown. Furthermore, deregulation of both MYB and miR-155 coupled with PU.1 downregulation was observed in human AML, suggesting that MYB/miR-155/PU.1 mechanism may be involved in the pathogenesis of AML and its aggressiveness characterized by p53 mutation.

AB - PU.1 downregulation within hematopoietic stem and progenitor cells (HSPCs) is the primary mechanism for the development of acute myeloid leukemia (AML) in mice with homozygous deletion of the upstream regulatory element (URE) of PU.1 gene. p53 is a well-known tumor suppressor that is often mutated in human hematologic malignancies including AML and adds to their aggressiveness; however, its genetic deletion does not cause AML in mouse. Deletion of p53 in the PU.1ure/ure mice (PU.1ure/ure p53-/) results in more aggressive AML with shortened overall survival. PU.1ure/urep53-/- progenitors express significantly lower PU.1 levels. In addition to URE deletion we searched for other mechanisms that in the absence of p53 contribute to decreased PU.1 levels in PU.1ure/urep53-/- mice. We found involvement of Myb and miR-155 in downregulation of PU.1 in aggressive murine AML. Upon inhibition of either Myb or miR-155 in vitro the AML progenitors restore PU.1 levels and lose leukemic cell growth similarly to PU.1 rescue. The MYB/miR-155/PU.1 axis is a target of p53 and is activated early after p53 loss as indicated by transient p53 knockdown. Furthermore, deregulation of both MYB and miR-155 coupled with PU.1 downregulation was observed in human AML, suggesting that MYB/miR-155/PU.1 mechanism may be involved in the pathogenesis of AML and its aggressiveness characterized by p53 mutation.

KW - AML

KW - Differentiation

KW - Leukemia

KW - microRNA

KW - p53

KW - PU.1

UR - http://www.scopus.com/inward/record.url?scp=84920839939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920839939&partnerID=8YFLogxK

U2 - 10.1038/onc.2013.414

DO - 10.1038/onc.2013.414

M3 - Article

VL - 33

SP - 4735

EP - 4745

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 39

ER -